SJS Investment Consulting Inc. Has $8.86 Million Position in Eli Lilly and Company (NYSE:LLY)

SJS Investment Consulting Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,892 shares of the company’s stock after buying an additional 53 shares during the quarter. Eli Lilly and Company accounts for 2.2% of SJS Investment Consulting Inc.’s portfolio, making the stock its 7th largest position. SJS Investment Consulting Inc.’s holdings in Eli Lilly and Company were worth $8,860,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Oxler Private Wealth LLC grew its holdings in Eli Lilly and Company by 0.4% during the first quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock valued at $2,078,000 after purchasing an additional 24 shares during the last quarter. Missouri Trust & Investment Co grew its stake in shares of Eli Lilly and Company by 3.2% in the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock worth $266,000 after acquiring an additional 24 shares during the last quarter. Silvercrest Asset Management Group LLC grew its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock worth $1,487,000 after acquiring an additional 25 shares during the last quarter. Cora Capital Advisors LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock worth $328,000 after acquiring an additional 26 shares during the last quarter. Finally, Sittner & Nelson LLC grew its stake in shares of Eli Lilly and Company by 2.7% in the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock worth $344,000 after acquiring an additional 26 shares during the last quarter. 81.38% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $0.21 on Tuesday, reaching $571.07. The stock had a trading volume of 1,085,815 shares, compared to its average volume of 3,026,357. The stock has a market cap of $542.11 billion, a P/E ratio of 80.02, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The company has a 50 day simple moving average of $512.56 and a 200 day simple moving average of $439.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same period in the previous year, the business earned $1.25 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company’s dividend payout ratio is 62.87%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Wells Fargo & Company raised their target price on Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. Argus raised their target price on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets lifted their price objective on Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $532.78.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 37,660 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the transaction, the insider now owns 100,275,279 shares of the company’s stock, valued at $54,825,684,274,988.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, major shareholder Lilly Endowment Inc sold 37,660 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the completion of the sale, the insider now owns 100,275,279 shares in the company, valued at $54,825,684,274,988.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alonzo Weems sold 1,148 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 976,153 shares of company stock valued at $21,080,192,113. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.